Table 1.

Clinical characteristics of patients by CLS-B status.

Characteristic	All Patients (n=237)	Patients without CLS-B (n=115)	Patients with CLS-B (n=122)	P
Age, years
Median (range)	48 (22–90)	47 (25–90)	49 (22–80)	0.38
Race, n (%)
Asian	14 (6.0%)	7 (6.1%)	7 (5.8%)
Black	17 (7.3%)	6 (5.3%)	11 (9.2%)
White	203 (86.8%)	101 (88.6%)	102 (85.0%)	0.55
BMI
Median (range)	25.3 (17.3–50.0)	23.1 (17.3–35.7)	28.3 (18.4–50.0)	<0.001
Menopausal status, n (%)
Pre	144 (60.8%)	80 (69.6%)	64 (52.5%)
Post	93 (39.2%)	35 (30.4%)	58 (47.5%)	0.008
Hypertension, n (%)
No	201 (84.8%)	102 (88.7%)	99 (81.2%)
Yes	36 (15.2%)	13 (11.3%)	23 (18.9%)	0.15
Diabetes, n (%)
No	227 (95.8%)	112 (97.4%)	115 (94.3%)
Yes	10 (4.2%)	3 (2.6%)	7 (5.7%)	0.34
NSAID use, n (%)
No	214 (90.3%)	102 (88.7%)	112 (91.8%)
Yes	23 (9.7%)	13 (11.3%)	10 (8.2%)	0.51
Statin use, n (%)
No	213 (89.9%)	104 (90.4%)	109 (89.3%)
Yes	24 (10.1%)	11 (9.6%)	13 (10.7%)	0.83
Mastectomy indication, n (%)
Treatment	211 (89.0%)	105 (91.3%)	106 (86.9%)
Risk reduction	26 (11.0%)	10 (8.7%)	16 (13.1%)	0.31
Estrogen receptor, n (%)
Negative	31 (18.7%)	16 (19.5%)	15 (17.9%)
Positive	135 (81.3%)	66 (80.5%)	69 (82.1%)	0.84
Unknown or NA	71 (30.0%)	33 (28.7%)	38 (31.2%)	0.78
Progesterone receptor, n (%)
Negative	45 (28.3%)	21 (26.6%)	24 (30.0%)
Positive	114 (71.7%)	58 (73.4%)	56 (70.0%)	0.73
Unknown or NA	78 (32.9%)	36 (31.3%)	42 (34.4%)	0.68
Preoperative hormonal therapy, n (%)
No	222 (93.7%)	108 (93.9%)	114 (93.4%)
Yes	15 (6.3%)	7 (6.1%)	8 (6.6%)	1.00
Preoperative chemotherapy, n (%)
No	203 (85.7%)	100 (87.0%)	103 (84.4%)
Yes	34 (14.3%)	15 (13.0%)	19 (15.6%)	0.71
BRCA mutation, n (%)
No	76 (60.8%)	44 (67.7%)	32 (53.3%)
Yes	49 (39.2%)	21 (32.3%)	28 (46.7%)	0.14
Unknown	112 (47.3%)	50 (43.5%)	62 (50.8%)	0.30

NSAID nonsteroidal anti-inflammatory drug; NA not applicable